ASCO: Pemetrexed extends survival as maintenance therapy

Bookmark and Share
Published: 18 Jun 2009
Views: 13176
Dr. Chandra P. Belani - Penn State Cancer Institute, Hershey, Pennsylvania, USA
ASCO press conference: A phase III study reports that maintenance therapy with pemetrexed (Alimta) improves overall survival in nonsquamous forms of advanced NSCLC.